Ocugen, Inc. (NASDAQ:OCGN) Stock Holdings Lifted by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Ocugen, Inc. (NASDAQ:OCGN) by 6.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,278,554 shares of the company’s stock after purchasing an additional 373,555 shares during the period. Geode Capital Management LLC owned 2.18% of Ocugen worth $6,231,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Barclays PLC lifted its stake in Ocugen by 104.3% in the third quarter. Barclays PLC now owns 581,087 shares of the company’s stock valued at $577,000 after acquiring an additional 296,654 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Ocugen during the 3rd quarter valued at $233,000. Wellington Management Group LLP acquired a new stake in shares of Ocugen in the 3rd quarter valued at $456,000. State Street Corp increased its position in Ocugen by 7.1% during the third quarter. State Street Corp now owns 15,824,517 shares of the company’s stock worth $15,701,000 after buying an additional 1,047,896 shares during the last quarter. Finally, MetLife Investment Management LLC raised its holdings in Ocugen by 36.4% during the third quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock valued at $89,000 after buying an additional 23,877 shares in the last quarter. Institutional investors own 10.27% of the company’s stock.

Ocugen Trading Down 0.6 %

Ocugen stock opened at $0.89 on Friday. Ocugen, Inc. has a 52 week low of $0.49 and a 52 week high of $2.11. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The firm has a market capitalization of $260.59 million, a PE ratio of -4.97 and a beta of 3.82. The business’s 50-day simple moving average is $0.90 and its 200-day simple moving average is $1.15.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on OCGN shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Ocugen in a research note on Monday, November 11th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Ocugen in a research report on Monday, November 18th. Finally, Maxim Group assumed coverage on shares of Ocugen in a research report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 price target on the stock.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.